The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019.
Dr Nicholas Vogelzang of the Comprehensive Cancer Centers of Nevada, Las Vegas, and colleagues presented updated safety data and efficacy of nivolumab in patients with non-clear cell renal cell carcinoma (RCC) in the CheckMate 374 study.
Results from the phase 3 CheckMate 374 study were analysed for patients with advanced or metastatic non-clear cell RCC who had received up to three prior systemic therapies.
There were 44 patients with non-clear cell RCC in CheckMate 374; including papillary (n = 24), chromophobe (n = 7), unclassified (n = 8), and other (n = 5). Most patients with non-clear cell RCC (66%) had not received systemic treatment.
For the non-clear cell RCC patients, median overall survival was 16.3 months, objective response rate was 13.6%, median duration of response was 10.2 months and median progression-free survival was 2.2 months. The safety results showed that a flat dose of 240 mg nivolumab every 2 weeks had a consistent safety profile across patients with clear and non-clear cell advanced RCC.
Nivolumab showed a response in several subtypes of RCC, and the safety profile was consistent with that reported across the whole nivolumab development programme.